Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ARGENX SE (ARGX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$894.77-3.93%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
38.46 → 37.10 EPS · FY ending Dec 31, 2027 · 9 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 9; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ARGX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain a strong competitive position in autoimmune therapies | Analysts project revenue to reach about $6.19 billion in FY26, driven by strong demand in autoimmune diseases. | Intact | market share falls below 25% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is best described as a Healthcare-sector exposure rather than a proven durable compounder or turnaround. The thesis state is insufficient because there is not enough recent financial performance history to assess it.
The evidence does not provide a valuation level or a clear account of what market expectations assume, so whether ARGX looks cheap, fair, or expensive versus peers is unclear. No fragility warning was triggered, but that alone does not establish that expectations are low.
The sector backdrop improved, rising from 7.6 to 18.0, which is a near-term tailwind for Healthcare names. Company-specific fundamentals are difficult to assess from the snapshot, and the near-term miss probability is 39%; the evidence also notes recent misses among industry peers.
Near term, continued earnings strength and higher guidance from VRTX, REGN, and MRNA could support the Healthcare backdrop, while misses or lower guidance could weaken it. A further risk is a weakening jobs report, which the evidence says can raise recession concerns for cyclical names and Healthcare stocks.
Over the next 1 to 3 years, the ARGX thesis remains unclear because company performance evidence is limited. The improved sector backdrop is supportive, but peer results and labor-market conditions are important near-term swing factors. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Sales for its leading therapy, Vyvgart, are expected to grow significantly. |
| Intact |
| regulatory approval is delayed beyond 2026 |
Qualitative condition This condition has no defined numerical measure. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
FY26 revenue growth from Vyvgart and other therapies | A primary condition in ARGENX SE's published investment case. The stated target is >=6.19 billion USD. | Intact | revenue falls below $5.5 billion in FY26 | Revenue: $2.816B FY2026-Q2; GAAP. Published target: >=6.19 billion USD. Annual target cannot be compared with a quarterly or TTM observation. Jul 23, 20262,815,766,309 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$37.19 → $37.10 · observed estimates
$7.31B → $7.99B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $37.19 | $7,305,153,100 | 18 / 31 |
| 2026-07-25 | $37.19 | $7,305,153,100 | 18 / 31 |
| 2026-07-26 | $37.73 | $7,553,769,820 | 17 / 31 |
| 2026-07-27 | $38.52 | $7,581,803,370 | 18 / 31 |
| 2026-07-28 | $38.52 | $7,581,803,370 | 18 / 31 |
| 2026-07-29 | $38.47 | $7,575,416,810 | 17 / 30 |
| 2026-07-30 | $38.47 | $7,575,416,810 | 17 / 30 |
| 2026-07-31 | $38.47 | $7,575,416,810 | 17 / 30 |
| 2026-08-01 | $39.12 | $7,593,990,150 | 16 / 30 |
| 2026-08-02 | $39.12 | $7,593,990,150 | 16 / 30 |
| 2026-08-03 | $39.12 | $7,593,990,150 | 16 / 30 |
| 2026-08-04 | $39.12 | $7,579,357,390 | 16 / 29 |
| 2026-08-05 | $38.81 | $7,591,936,700 | 17 / 29 |
| 2026-08-06 | $38.81 | $7,591,936,700 | 17 / 29 |
| 2026-08-07 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-08 | $39.56 | $7,610,741,130 | 16 / 29 |
| 2026-08-09 | $39.56 | $7,610,741,130 | 16 / 29 |
| 2026-08-10 | $39.56 | $7,610,741,130 | 16 / 29 |
| 2026-08-11 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-12 | $39.56 | $7,610,741,130 | 16 / 29 |
| 2026-08-13 | $39.56 | $7,610,741,130 | 16 / 29 |
| 2026-08-14 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-15 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-16 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-17 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-18 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-19 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-20 | $37.55 | $7,536,590,754 | 13 / 20 |
| 2026-08-21 | $38.44 | $7,615,913,853 | 12 / 20 |
| 2026-08-22 | $38.44 | $7,615,913,853 | 13 / 20 |
| 2026-08-23 | $38.44 | $7,615,913,853 | 13 / 20 |
| 2026-08-24 | $38.44 | $7,615,913,853 | 13 / 20 |
| 2026-08-25 | $38.46 | $7,620,042,885 | 13 / 20 |
| 2026-08-26 | $38.46 | $7,620,042,885 | 13 / 20 |
| 2026-08-27 | $38.46 | $7,620,042,885 | 13 / 20 |
| 2026-08-28 | $38.46 | $7,620,042,885 | 13 / 20 |
| 2026-08-29 | $38.58 | $7,646,400,280 | 13 / 20 |
| 2026-08-30 | $38.58 | $7,646,400,287 | 13 / 20 |
| 2026-08-31 | $38.58 | $7,646,400,287 | 13 / 20 |
| 2026-09-01 | $38.58 | $7,646,400,287 | 13 / 20 |
| 2026-09-02 | $38.76 | $7,646,400,287 | 13 / 20 |
| 2026-09-03 | $38.56 | $7,646,790,848 | 13 / 20 |
| 2026-09-04 | $38.60 | $7,658,174,719 | 13 / 20 |
| 2026-09-05 | $38.60 | $7,658,174,719 | 13 / 20 |
| 2026-09-06 | $38.60 | $7,658,174,719 | 13 / 20 |
| 2026-09-07 | $38.60 | $7,658,174,719 | 13 / 20 |
| 2026-09-08 | $38.60 | $7,658,174,719 | 13 / 20 |
| 2026-09-09 | $38.63 | $7,658,174,719 | 13 / 20 |
| 2026-09-10 | $38.63 | $7,658,174,719 | 13 / 20 |
| 2026-09-11 | $38.63 | $7,658,174,719 | 13 / 20 |
| 2026-09-12 | $38.63 | $7,658,174,719 | 13 / 20 |
| 2026-09-13 | $38.63 | $7,658,174,719 | 13 / 20 |
| 2026-09-14 | $38.63 | $7,658,174,719 | 8 / 12 |
| 2026-09-15 | $38.54 | $7,662,181,171 | 8 / 12 |
| 2026-09-16 | $38.54 | $7,662,181,171 | 8 / 12 |
| 2026-09-17 | $38.49 | $7,659,310,203 | 8 / 12 |
| 2026-09-18 | $38.49 | $7,659,310,203 | 8 / 12 |
| 2026-09-19 | $38.49 | $7,659,310,203 | 8 / 12 |
| 2026-09-20 | $38.48 | $7,657,966,155 | 8 / 12 |
| 2026-09-21 | $38.48 | $7,657,966,155 | 8 / 12 |
| 2026-09-22 | $38.44 | $7,657,966,155 | 8 / 12 |
| 2026-09-23 | $38.44 | $7,657,966,264 | 8 / 12 |
| 2026-09-24 | $38.44 | $7,657,966,188 | 8 / 12 |
| 2026-09-25 | $38.44 | $7,657,966,188 | 8 / 12 |
| 2026-09-26 | $38.44 | $7,657,966,188 | 8 / 12 |
| 2026-09-27 | $38.46 | $7,662,867,059 | 8 / 12 |
| 2026-09-28 | $38.46 | $7,662,867,059 | 8 / 12 |
| 2026-09-29 | $38.46 | $7,662,867,059 | 8 / 12 |
| 2026-09-30 | $38.46 | $7,662,867,059 | 8 / 12 |
| 2026-10-01 | $38.46 | $7,662,867,069 | 8 / 12 |
| 2026-10-02 | $38.46 | $7,662,867,069 | 8 / 12 |
| 2026-10-03 | $38.46 | $7,662,867,069 | 8 / 12 |
| 2026-10-04 | $38.46 | $7,662,867,069 | 8 / 12 |
| 2026-10-05 | $38.46 | $7,662,867,069 | 8 / 12 |
| 2026-10-06 | $38.46 | $7,662,168,157 | 8 / 12 |
| 2026-10-07 | $38.46 | $7,662,169,709 | 8 / 12 |
| 2026-10-08 | $38.46 | $7,662,169,709 | 8 / 12 |
| 2026-10-09 | $39.04 | $7,687,625,077 | 8 / 12 |
| 2026-10-10 | $39.04 | $7,687,625,077 | 8 / 12 |
| 2026-10-11 | $38.99 | $7,692,093,745 | 8 / 12 |
| 2026-10-12 | $38.99 | $7,692,093,745 | 8 / 12 |
| 2026-10-13 | $39.14 | $7,704,594,975 | 8 / 12 |
| 2026-10-14 | $39.11 | $7,702,357,940 | 8 / 12 |
| 2026-10-15 | $39.01 | $7,702,809,518 | 8 / 12 |
| 2026-10-16 | $39.01 | $7,702,380,211 | 8 / 12 |
| 2026-10-17 | $39.01 | $7,702,380,211 | 8 / 12 |
| 2026-10-18 | $39.01 | $7,702,610,711 | 8 / 12 |
| 2026-10-19 | $39.01 | $7,702,610,711 | 8 / 12 |
| 2026-10-20 | $39.01 | $7,702,610,711 | 8 / 12 |
| 2026-10-21 | $39.06 | $7,717,507,586 | 8 / 12 |
| 2026-10-22 | $38.98 | $7,717,923,824 | 8 / 12 |
| 2026-10-23 | $37.72 | $7,869,657,977 | 9 / 12 |
| 2026-10-24 | $37.91 | $7,901,925,227 | 9 / 12 |
| 2026-10-25 | $37.91 | $7,901,925,227 | 8 / 12 |
| 2026-10-26 | $37.91 | $7,901,925,227 | 8 / 12 |
| 2026-10-27 | $37.91 | $7,901,925,227 | 8 / 12 |
| 2026-10-28 | $37.65 | $7,930,690,729 | 9 / 12 |
| 2026-10-29 | $37.66 | $7,930,691,185 | 9 / 12 |
| 2026-10-30 | $37.66 | $7,930,691,185 | 9 / 12 |
| 2026-10-31 | $37.66 | $7,930,691,185 | 9 / 12 |
| 2026-11-01 | $37.08 | $7,961,939,288 | 9 / 12 |
| 2026-11-02 | $37.08 | $7,961,939,288 | 9 / 12 |
| 2026-11-03 | $37.08 | $7,961,939,288 | 9 / 12 |
| 2026-11-04 | $37.10 | $7,986,229,612 | 9 / 12 |
| 2026-11-05 | $37.10 | $7,986,229,612 | 9 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 20 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 11 recorded
2 raises · 4 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.